BR112019008279A2 - uso de beta-catenina como um biomarcador para tratamento de cânceres usando anticorpo anti-dkk-1 - Google Patents
uso de beta-catenina como um biomarcador para tratamento de cânceres usando anticorpo anti-dkk-1Info
- Publication number
- BR112019008279A2 BR112019008279A2 BR112019008279A BR112019008279A BR112019008279A2 BR 112019008279 A2 BR112019008279 A2 BR 112019008279A2 BR 112019008279 A BR112019008279 A BR 112019008279A BR 112019008279 A BR112019008279 A BR 112019008279A BR 112019008279 A2 BR112019008279 A2 BR 112019008279A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- dkk
- antibody
- biomarker
- cancer treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Abstract
é divulgado um método de tratamento de um câncer em um sujeito com sua necessidade. o câncer pode ser um câncer esofágico, um câncer uterino, um câncer do fígado ou um colangiocarcinoma. o método compreende administração ao sujeito de uma quantidade eficaz de um anticorpo anti-dkk-1 ou seu fragmento de ligação ao antígeno, em que é determinado que o sujeito tem uma mutação constitutivamente ativante da proteína beta-catenina
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662413198P | 2016-10-26 | 2016-10-26 | |
PCT/US2017/058555 WO2018081437A1 (en) | 2016-10-26 | 2017-10-26 | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019008279A2 true BR112019008279A2 (pt) | 2019-07-09 |
Family
ID=60570180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019008279A BR112019008279A2 (pt) | 2016-10-26 | 2017-10-26 | uso de beta-catenina como um biomarcador para tratamento de cânceres usando anticorpo anti-dkk-1 |
Country Status (14)
Country | Link |
---|---|
US (2) | US11267876B2 (pt) |
EP (1) | EP3532099A1 (pt) |
JP (2) | JP7374765B2 (pt) |
KR (1) | KR20190085935A (pt) |
CN (1) | CN110114087A (pt) |
AU (1) | AU2017347822A1 (pt) |
BR (1) | BR112019008279A2 (pt) |
CA (1) | CA3041325A1 (pt) |
IL (1) | IL266199A (pt) |
MA (1) | MA46673A (pt) |
MX (1) | MX2019004940A (pt) |
RU (1) | RU2019115946A (pt) |
SG (1) | SG11201903602RA (pt) |
WO (1) | WO2018081437A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2019115946A (ru) | 2016-10-26 | 2020-11-27 | Лип Терапьютикс, Инк. | Применение бета-катенина в качестве биомаркера для лечения форм рака с помощью антитела к dkk-1 |
AU2020216494A1 (en) * | 2019-02-01 | 2021-08-12 | Board Of Regents, The University Of Texas System | Monoclonal antibodies against MHC-bound human Dickkopf-1 peptides and uses thereof |
WO2021055789A1 (en) * | 2019-09-19 | 2021-03-25 | Leap Therapeutics, Inc. | Use of dkk-1 inhibitors for treating cancer |
JP2023502666A (ja) * | 2019-11-22 | 2023-01-25 | リープ セラピューティクス,インコーポレイテッド | Dkk-1阻害剤を用いて癌を処置する方法 |
WO2023183940A2 (en) * | 2022-03-24 | 2023-09-28 | The Translational Genomics Research Institute | Peptide inhibitors targeting the tbl1-beta-catenin complex |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US7446181B2 (en) * | 1998-01-15 | 2008-11-04 | Millennium Pharmaceuticals, Inc. | Antibodies that bind human Dickkopf-1 proteins |
AR060017A1 (es) | 2006-01-13 | 2008-05-21 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de dickkopf -1 |
WO2008097510A1 (en) | 2007-02-08 | 2008-08-14 | Merck & Co., Inc. | Antibodies specific for dkk-1 |
AR075989A1 (es) | 2009-04-10 | 2011-05-11 | Lilly Co Eli | Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria |
CN103608037B (zh) * | 2011-02-01 | 2016-04-13 | 香港大学 | 抗dkk1单克隆抗体用于治疗肝癌的用途 |
ES2703208T3 (es) | 2013-02-27 | 2019-03-07 | Daiichi Sankyo Co Ltd | Método de predicción de la sensibilidad a un compuesto que inhibe la vía de transducción de señales de MAPK |
CA2931975A1 (en) * | 2013-12-02 | 2015-06-11 | Oncomed Pharmaceuticals, Inc. | Identification of predictive biomarkers associated with wnt pathway inhibitors |
RU2019115946A (ru) | 2016-10-26 | 2020-11-27 | Лип Терапьютикс, Инк. | Применение бета-катенина в качестве биомаркера для лечения форм рака с помощью антитела к dkk-1 |
-
2017
- 2017-10-26 RU RU2019115946A patent/RU2019115946A/ru unknown
- 2017-10-26 MA MA046673A patent/MA46673A/fr unknown
- 2017-10-26 SG SG11201903602RA patent/SG11201903602RA/en unknown
- 2017-10-26 EP EP17808633.6A patent/EP3532099A1/en active Pending
- 2017-10-26 JP JP2019522823A patent/JP7374765B2/ja active Active
- 2017-10-26 BR BR112019008279A patent/BR112019008279A2/pt unknown
- 2017-10-26 CA CA3041325A patent/CA3041325A1/en active Pending
- 2017-10-26 CN CN201780071597.0A patent/CN110114087A/zh active Pending
- 2017-10-26 MX MX2019004940A patent/MX2019004940A/es unknown
- 2017-10-26 KR KR1020197014600A patent/KR20190085935A/ko not_active Application Discontinuation
- 2017-10-26 AU AU2017347822A patent/AU2017347822A1/en active Pending
- 2017-10-26 US US16/345,191 patent/US11267876B2/en active Active
- 2017-10-26 WO PCT/US2017/058555 patent/WO2018081437A1/en unknown
-
2019
- 2019-04-23 IL IL266199A patent/IL266199A/en unknown
-
2022
- 2022-01-28 US US17/587,708 patent/US20220289831A1/en active Pending
-
2023
- 2023-07-26 JP JP2023121862A patent/JP2023133432A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN110114087A (zh) | 2019-08-09 |
JP2023133432A (ja) | 2023-09-22 |
JP2019533693A (ja) | 2019-11-21 |
AU2017347822A1 (en) | 2019-05-09 |
US20190284264A1 (en) | 2019-09-19 |
MA46673A (fr) | 2019-09-04 |
US11267876B2 (en) | 2022-03-08 |
MX2019004940A (es) | 2019-09-26 |
IL266199A (en) | 2019-06-30 |
RU2019115946A (ru) | 2020-11-27 |
JP7374765B2 (ja) | 2023-11-07 |
EP3532099A1 (en) | 2019-09-04 |
KR20190085935A (ko) | 2019-07-19 |
US20220289831A1 (en) | 2022-09-15 |
CA3041325A1 (en) | 2018-05-03 |
RU2019115946A3 (pt) | 2021-01-26 |
WO2018081437A1 (en) | 2018-05-03 |
SG11201903602RA (en) | 2019-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019008279A2 (pt) | uso de beta-catenina como um biomarcador para tratamento de cânceres usando anticorpo anti-dkk-1 | |
BR112016005816A2 (pt) | Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores | |
BR112018002824A2 (pt) | anticorpo, polinucleotídeo, vetor, célula, métodos para expressar o anticorpo, para tratar uma condição associada com pd-1 e para tratar uma condição em um sujeito, kit, composição farmacêutica e uso do anticorpo | |
BR112019005823A2 (pt) | tratamento para enxaqueca refratária | |
BR112019000436A2 (pt) | anticorpos anti-pd-1, método de produção e método de uso dos mesmos | |
BR112018002274A2 (pt) | anticorpos anti-pd-1 | |
BR112017022845A2 (pt) | neoepítopos de câncer | |
BR112017010762A2 (pt) | anticorpos anti-pd-1 e métodos de uso dos mesmos | |
BR112017002342A2 (pt) | novos anticorpos e usos dos mesmos | |
BR112018011336A2 (pt) | anticorpo anti-fcrl5 isolado ou um fragmento de ligação ao antígeno do mesmo, anticorpo scfv anti-fcrl5 isolado, anticorpo isolado ou porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico isolado, vetor de expressão, célula hospedeira, método para detectar fcrl5 em uma célula ou tecido inteiro, método para tratar câncer em um indivíduo, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo, kit para tratar câncer | |
BR112017023849A2 (pt) | anticorpos anti-ox40 e métodos de uso dos mesmos | |
BR112015021979A2 (pt) | Anticorpos humanos para grem1 | |
BR112017026330A2 (pt) | molécula de ligação de lag-3 capaz de ligação tanto o lag-3 humano quanto ao lag-3 de macaco cynomolgus | |
BR112016030908A2 (pt) | moléculas com especificidade para cd45 e cd79 | |
BR112016026197A2 (pt) | anticorpos anti-b7-h1 e anti-ctla-4 para o tratamento de câncer de pulmão de não pequenas células | |
BR112017011235A2 (pt) | anticorpos anti-c5 e métodos de uso | |
BR112017001579A2 (pt) | anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos | |
BR112017008914A2 (pt) | método para tratar câncer, composição e uso da composição | |
BR112016020752A2 (pt) | ?anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, métodos para tratamento de um câncer ou tumor expressando egfrviii e para tratamento de um câncer, redução de crescimento de tumor e/ou causação de regressão de tumor em um paciente? | |
BR112016017248A8 (pt) | anticorpo ou fragmento seu, agente de ligação, animal transgênico, hibridoma, vetor, composição farmacêutica, método de indução de sinalização de semelhantes a fgf19 e/ou fgf21, método para ativar um complexo klotho beta/receptor de fgf, método para melhorar o metabolismo da glicose em um indivíduo, método de detecção da presença de klotho beta, uso do anticorpo ou fragmento seu, uso da composição farmacêutica, método de tratamento e método para melhorar parâmetros metabólicos | |
EA201591806A1 (ru) | Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител | |
BR112017000671A2 (pt) | moléculas com especificidade para cd79 e cd22 | |
BR112016026993A2 (pt) | combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer | |
BR112016014293A2 (pt) | região de fragmento cristalizável canino, anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, e, método para aumentar a atividade de uma célula imune | |
BR112015007184A2 (pt) | combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |